InsidersTradesSigma
Follow the Plus Therapeutics, INC. share price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Plus Therapeutics, INC. has logged 49 public disclosures. Market capitalisation: €26.6m. The latest transaction was filed on 1 July 2026 (Levée d'options). Among the most active insiders: HEDRICK MARC H. Every trade is accessible without an account.
49
Insider Decl.
n/a
Thresholds
€343,464
37 ops.
Buy Volume
€4,158
2 ops.
Sell Volume
59Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 1 July 2026
Declarations49 total
922 sharesCommon StockSEC:0001193125-26-292654:0
922 sharesCommon StockSEC:0001193125-26-292639:0
159,681 shares0Common StockSEC:0001193125-26-135710:0
201,632 shares0Common StockSEC:0001193125-26-135710:1
38,323 shares0Common StockSEC:0001193125-26-135711:0
29,129 shares0Common StockSEC:0001193125-26-135711:1
159,681 shares0Common StockSEC:0001193125-26-000967:0
38,323 shares0Common StockSEC:0001193125-26-000966:0
20,000 shares@ US$0.5125.5% of flowCommon StockSEC:0001193125-25-265866:0
Canonical exit: 2 Feb 2026 (T+90)
159,681 shares0Common StockSEC:0001193125-25-230296:0
38,323 shares0Common StockSEC:0001193125-25-230291:0
110,000 shares@ US$0.488958.1% of flowCommon StockSEC:0000950170-25-111092:0
Canonical exit: 20 Nov 2025 (T+90)
4,000 shares@ US$1.49923.2% of flowCommon StockSEC:0000950170-24-107008:0
Canonical exit: 12 Dec 2024 (T+90)
6,285 shares@ US$1.354332.9% of flowCommon StockSEC:0000950170-24-106605:0
Canonical exit: 11 Dec 2024 (T+90)
12,500 shares@ US$1.3512.5% of flowCommon StockSEC:0000950170-24-106180:0
Canonical exit: 10 Dec 2024 (T+90)
5,000 shares@ US$1.336211.2% of flowCommon StockSEC:0000950170-24-106179:0
Canonical exit: 10 Dec 2024 (T+90)
8,000 shares@ US$1.229915.1% of flowCommon StockSEC:0000950170-24-105331:0
Canonical exit: 9 Dec 2024 (T+90)
4,098 shares@ US$1.2714.0% of flowCommon StockSEC:0000950170-24-105330:0
Canonical exit: 9 Dec 2024 (T+90)
4,902 shares@ US$2.0427.6% of flowCommon StockSEC:0000950170-24-057456:0
Canonical exit: 6 Aug 2024 (T+90)
4,902 shares@ US$2.0439.9% of flowCommon StockSEC:0000950170-24-057453:0
Canonical exit: 6 Aug 2024 (T+90)
12,255 shares@ US$2.0439.3% of flowCommon StockSEC:0000950170-24-057455:0
Canonical exit: 6 Aug 2024 (T+90)
4,167 shares@ US$2.0417.8% of flowCommon StockSEC:0000950170-24-057451:0
Canonical exit: 6 Aug 2024 (T+90)
12,255 shares@ US$2.0418.9% of flowCommon StockSEC:0000950170-24-057454:0
Canonical exit: 6 Aug 2024 (T+90)
9,804 shares@ US$2.0434.5% of flowCommon StockSEC:0000950170-24-057452:0
Canonical exit: 6 Aug 2024 (T+90)
2,068 shares@ US$1.95976.3% of flowCommon StockSEC:0001209191-23-058816:0
25 of 49 declarations
关于 Plus Therapeutics, INC.
Plus Therapeutics, Inc. (股票代码: PSTV) 是一家美国生物技术公司，在美国纳斯达克资本市场上市。该公司专注于精准肿瘤学，其临床阶段平台以中枢神经系统 (CNS) 癌症的靶向放射治疗和诊断为核心，特别是针对难治性和罕见疾病。公司总部位于德克萨斯州休斯顿，并在德克萨斯州设有额外的实验室和洁净室设施，使其拥有结合研究、临床前工作、生产支持以及邻近领先癌症机构的混合开发模式。([plustherapeutics.com](https://plustherapeutics.com/about-us/?utm_source=openai)) 公司历史可追溯至1996年，但其目前的身份反映了向放射性药物肿瘤学的战略转变。随着时间的推移，Plus Therapeutics 已将其产品组合重新定位，围绕铼基疗法和先进的递送技术，包括纳米脂质体配方和放射性同位素加载方法，旨在提供局部β辐射，同时限制脱靶暴露。这一演变使业务更加专注和专业化，明确强调将靶向辐射科学转化为临床相关的癌症疗法。([stockanalysis.com](https://stockanalysis.com/stocks/pstv/company/?utm_source=openai)) 其产品组合的核心是REYOBIQ™，这是该公司针对脑膜转移 (LM) 和复发性胶质母细胞瘤 (GBM) 等中枢神经系统癌症的领先项目。同时，Plus Therapeutics 正在通过其全资子公司CNSide Diagnostics建立CNSide Diagnostics，旨在支持中枢神经系统癌症护理中更精确的检测和监测。因此，该公司的商业模式涵盖治疗和诊断，这在肿瘤学环境中具有战略相关性，因为治疗选择和疾病监测可以实质性地影响结果。([ir.plustherapeutics.com](https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-provides-business-update-cnside-diagnostics/?utm_source=openai)) 从竞争角度来看，Plus Therapeutics 在肿瘤学高度专业化的领域中占据了一个利基位置。它不作为一家大型制药公司进行广泛竞争；相反，它旨在通过针对临床需求仍然很高的未满足癌症的靶向放射治疗平台来实现差异化。其竞争优势在于其专注性、专有配方技术以及将图像引导的局部辐射递送与支持规模化的制造合作伙伴关系相结合的能力。该公司已扩大与第三方放射性药物制造商（如SpectronRx和Telix IsoTherapeutics）的合作，以确保铼-186的供应并提高开发冗余。([ir.plustherapeutics.com](https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-and-spectronrx-announce-radiotherapeutic?utm_source=openai)) 近期里程碑包括在2026年3月发布2025财年全年业绩，以及REYOBIQ和CNSide的近期临床和商业目标的更新。在2025年期间，该公司还报告了纳斯达克股东权益合规性的改善，并继续寻求资金和运营举措以支持后期开发。对于投资者而言，Plus Therapeutics 仍然是一个高风险、催化剂驱动的微型生物技术故事，其价值主张取决于临床开发、监管进展和工业规模化方面的执行。([nasdaq.com](https://www.nasdaq.com/press-release/plus-therapeutics-reports-2025-results-business-progress-and-2026-anticipated?utm_source=openai))
